Affinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM

Affinia Therapeutics Secures Health Canada Clearance to Launch UPBEAT© Phase 1/2 Trial Evaluating AFTX-201 for BAG3-Related Dilated Cardiomyopathy Affinia Therapeutics, a clinical-stage biotechnology company focused on advancing next-generation gene therapies…

Read MoreAffinia Therapeutics Secures Health Canada Approval to Launch Phase 1/2 UPBEAT Trial of AFTX-201 in BAG3-Related DCM

Allevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System for Spinal Decompression

Allevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System Designed for Advanced Spinal Decompression Allevion Medical has announced that it has received clearance from the U.S. Food…

Read MoreAllevion Medical™ Secures 510(k) Clearance for Vantage™, an Innovative Fully Disposable System for Spinal Decompression

Armatus Unveils Breakthrough Data Advancing TVR110 MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A

Armatus Reports Promising Breakthrough Data on TVR110, a Vectorized MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A Armatus Bio, a late-preclinical biotechnology company focused on developing next-generation vectorized RNA interference (RNAi)…

Read MoreArmatus Unveils Breakthrough Data Advancing TVR110 MicroRNA Therapy for Charcot-Marie-Tooth Disease Type 1A

PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal

PureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal PureTech Health plc, a clinical-stage biotherapeutics company focused on translating cutting-edge science into transformative therapies,…

Read MorePureTech Reports Publication of Phase 2b ELEVATE IPF Trial Results in Leading Respiratory Medicine Journal